Literature DB >> 12232850

Cognitive impairment in adults with good recovery after bacterial meningitis.

Diederik van de Beek1, Ben Schmand, Jan de Gans, Martijn Weisfelt, Heleen Vaessen, Jacob Dankert, Marinus Vermeulen.   

Abstract

Adults without neurologic sequelae after bacterial meningitis are supposed to live without restrictions. Neuropsychological outcome was assessed in 51 adults from a prospective cohort with good recovery, defined as Glasgow Outcome Scale score 5, after pneumococcal or meningococcal meningitis. Patients who recovered well after pneumococcal meningitis showed cognitive slowness (P=.001). A cognitive disorder was found in 27% of these patients. Patients who previously had meningococcal meningitis were not significantly different from control subjects. Scores on general health and quality of life questionnaires revealed lower scores for patients with meningitis, which were related to cognitive slowing (R, -0.46 to -0.38). In conclusion, adults surviving pneumococcal meningitis were at significant risk of neuropsychological abnormalities, even if they were clinically well recovered.

Entities:  

Mesh:

Year:  2002        PMID: 12232850     DOI: 10.1086/344229

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  45 in total

Review 1.  Reprogramming the host response in bacterial meningitis: how best to improve outcome?

Authors:  M van der Flier; S P M Geelen; J L L Kimpen; I M Hoepelman; E I Tuomanen
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

Review 2.  Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis.

Authors:  Matthijs C Brouwer; Allan R Tunkel; Diederik van de Beek
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

3.  Pathophysiology and treatment of bacterial meningitis.

Authors:  Olaf Hoffman; R Joerg Weber
Journal:  Ther Adv Neurol Disord       Date:  2009-11       Impact factor: 6.570

4.  Adjunctive Corticosteroids in Adults with Bacterial Meningitis.

Authors:  Diederik van de Beek; Jan de Gans
Journal:  Curr Infect Dis Rep       Date:  2005-07       Impact factor: 3.725

Review 5.  Pathogenesis and pathophysiology of pneumococcal meningitis.

Authors:  Barry B Mook-Kanamori; Madelijn Geldhoff; Tom van der Poll; Diederik van de Beek
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

6.  Genetic variation in inflammasome genes is associated with outcome in bacterial meningitis.

Authors:  Madelijn Geldhoff; Barry B Mook-Kanamori; Matthijs C Brouwer; Mercedes Valls Seron; Frank Baas; Arie van der Ende; Diederik van de Beek
Journal:  Immunogenetics       Date:  2012-09-30       Impact factor: 2.846

7.  Folic acid prevented cognitive impairment in experimental pneumococcal meningitis.

Authors:  Tatiana Barichello; Jaqueline S Generoso; Lutiana R Simões; Amanda V Steckert; Ana Paula Moreira; Diogo Dominguini; Pâmela Ferrari; Carolina Gubert; Flávio Kapczinski; Luciano K Jornada; Lucineia G Danielski; Fabricia Petronilho; Josiane Budni; João Quevedo
Journal:  J Neural Transm (Vienna)       Date:  2014-09-19       Impact factor: 3.575

8.  TRAIL limits excessive host immune responses in bacterial meningitis.

Authors:  Olaf Hoffmann; Josef Priller; Timour Prozorovski; Ulf Schulze-Topphoff; Nevena Baeva; Jan D Lunemann; Orhan Aktas; Cordula Mahrhofer; Sarah Stricker; Frauke Zipp; Joerg R Weber
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

9.  Neurocritical care of patients with central nervous system infections.

Authors:  Andreas H Kramer; Thomas P Bleck
Journal:  Curr Treat Options Neurol       Date:  2008-05       Impact factor: 3.598

10.  Role of the cathelicidin-related antimicrobial peptide in inflammation and mortality in a mouse model of bacterial meningitis.

Authors:  Julika Merres; Jonas Höss; Lea-Jessica Albrecht; Eugenia Kress; Oliver Soehnlein; Sandra Jansen; Thomas Pufe; Simone C Tauber; Lars-Ove Brandenburg
Journal:  J Innate Immun       Date:  2013-08-22       Impact factor: 7.349

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.